Latest Breaking News On - Neuroscience development - Page 1 : vimarsana.com

Bristol Myers: new data on schizophrenia -April 08, 2024 at 04:52 am EDT

Bristol Myers Squibb presents new interim pooled long-term safety and metabolic outcome data from the EMERGENT program evaluating KarXT in schizophrenia at the 2024 Annual Meeting of the International.

Bristol Myers Squibb to Present Data at on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

AbbVie's Ubrelvy "significantly" reduces migraine headache pain

AbbVie Inc on Thursday said Ubrelvy reduces the headache phase of a migraine attack. The North Chicago, Illinois-based pharmaceutical company said Ubrelvy is the first and only acute treatment for.

FDA Grants Breakthrough Therapy Designation to Novel Drug for Progressive Pulmonary Fibrosis

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis

Designation is based on results from the progressive pulmonary fibrosis cohort of the Phase 2 study assessing the safety and efficacy of BMS-986278 treatment versus placebo .

Novel Antifibrotic Designated Breakthrough Therapy for Progressive Pulmonary Fibrosis

The FDA has granted Breakthrough Therapy designation to BMS-986278, an investigational LPA1 antagonist, for progressive pulmonary fibrosis.

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up t

Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any.

Bristol-Myers Squibb (BMY) Reports Sotyktu Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Bristol-Myers Squibb (BMY) Presents New Zeposia Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis